8-K: Applied Therapeutics Reports $17.4M Equity, Faces Nasdaq Delisting

Applied Therapeutics, Inc. announced preliminary unaudited stockholders' equity of $17.4 million as of June 30, 2025, while actively addressing a Nasdaq delisting threat due to its stock price.

Summary

• Preliminary unaudited stockholders' equity as of June 30, 2025, is estimated at approximately $17.4 million.
• The company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025.
• A Nasdaq notification was received on February 7, 2025, for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days.
• The initial 180-day compliance period to regain the bid price requirement expired on August 6, 2025.
• An application has been submitted to transfer the listing from the Nasdaq Global Market to the Nasdaq Capital Market to potentially gain an additional 180-day remediation period.
• Management believes the company meets all Nasdaq Capital Market listing standards, except for the bid price, including the minimum $5 million stockholders' equity requirement.
• Nasdaq has not yet approved the transfer application or granted the additional compliance period.
• Complete financial results for Q2 2025 are expected to be filed in the Form 10-Q and earnings release on August 13, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the immediate threat of Nasdaq delisting and the expiration of the initial compliance period. While the company is taking steps to mitigate this, the outcome is uncertain. The preliminary financial results, while meeting a minimum threshold for a different market, are still low and unaudited, adding to the uncertainty.

Positives

• Management believes the company meets the minimum $5 million stockholders' equity requirement for the Nasdaq Capital Market, a prerequisite for transfer.
• The company has proactively submitted an application to transfer to the Nasdaq Capital Market to seek an extended compliance period for the bid price deficiency.

Negatives

• The company's common stock bid price has been below the minimum $1.00 requirement for continued listing on Nasdaq.
• The initial 180-day period to regain compliance with the Nasdaq bid price requirement expired on August 6, 2025, without compliance being met.
• There is no assurance that Nasdaq will grant the application to transfer to the Nasdaq Capital Market or provide an additional 180-day remediation period.
• The preliminary financial estimates are unaudited and subject to material changes upon completion of the financial close process.
• Ernst & Young LLP has not audited, reviewed, or expressed an opinion on the preliminary financial data.

Risks

• Actual financial results as of June 30, 2025, may differ materially from preliminary estimates due to final adjustments and other developments.
• There is no assurance that the Common Stock will be transferred to the Nasdaq Capital Market.
• There is a risk that the Common Stock will be delisted from Nasdaq if compliance is not regained or the transfer is not approved.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates filing its complete financial results for the quarter ended June 30, 2025, in its Form 10-Q and earnings release on August 13, 2025. It is also awaiting Nasdaq's determination regarding its application to transfer to the Nasdaq Capital Market, which could provide an additional 180-day period to regain compliance with the bid price requirement.

Management Comments

• "The foregoing information is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2025, is not a comprehensive statement of the Company's financial results, and is subject to completion of the Company's financial closing procedures."
• "The Company believes that it meets the continued listing requirement for market value of publicly held shares and all initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, including the minimum $5 million stockholders' equity requirement."

Industry Context

The filing does not provide specific details to contextualize the company's financial performance or Nasdaq listing issues within broader industry trends. However, maintaining Nasdaq listing is crucial for public companies, especially in capital-intensive sectors like biotechnology, to ensure liquidity and access to capital markets.

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the company's continued listing on Nasdaq, which could impact stock liquidity and valuation. The preliminary financial results provide limited insight into the company's health.
• Investors: Potential for increased volatility and risk due to delisting threat and unaudited financial data.

Next Steps

• Completion of the company's financial close process for the quarter ended June 30, 2025.
• Filing of the Quarterly Report on Form 10-Q for Q2 2025 and corresponding earnings release on August 13, 2025.
• Nasdaq's determination regarding the company's application to transfer its listing to the Nasdaq Capital Market.
• If approved for the Nasdaq Capital Market, the company would need to cure the bid price deficiency, potentially through a reverse stock split, during an additional 180-day remediation period.

Key Dates

Recommendation

The company faces an immediate and significant risk of delisting from Nasdaq, as the initial compliance period for the bid price requirement has expired without resolution. While an application to transfer to the Nasdaq Capital Market has been submitted, its approval is not guaranteed, and even if approved, the company would still need to regain bid price compliance, potentially through a dilutive reverse stock split. The preliminary unaudited financial results, while meeting a minimum threshold for a secondary market, do not provide a strong basis for confidence, and the lack of external audit on these preliminary figures adds to the uncertainty. The overall situation presents substantial downside risk and a lack of clear positive catalysts, making a 'sell' recommendation prudent for risk-averse investors.

Keywords

Applied Therapeutics, APLT, SEC Filing, 8-K, Stockholders Equity, Nasdaq Listing, Delisting Threat, Bid Price Rule, Financial Estimates, Biotech, Pharmaceuticals